BioSpace News Archive

Ophthalmology: Horus Pharma distributes ILUVIEN® in France

Horus Pharma, an independent laboratory specialized in ophthalmology, announces that it is now making ILUVIEN® available to French patients. ILUVIEN is owned by Alimera Sciences, Inc. (US).

May 21, 2019
·
4 min read
Drug Development

First patient treated in DIAMOND study to evaluate if Veltassa® (patiromer) improves outcomes by enabling long-term use of essential RAASi therapy

Vifor Pharma announced that treatment of the first patient in their global phase-IIIb DIAMOND study has begun.

May 21, 2019
·
7 min read
Deals

Poxel Announces Participation at Two Upcoming Investor Conferences and Imeglimin Presentation at the Japanese Diabetes Society

POXEL S.A. announced that it will be featured as a presenting company at the Jefferies 2019 Global Healthcare Conference and the JMP Securities Life Sciences Conference.

May 21, 2019
·
3 min read
Deals

Oncopeptides AB: INTERIM REPORT Q1 2019

The initiation of the filing process for melflufen in the US is a major milestone for Oncopeptides.

May 21, 2019
·
3 min read
Sofinnova Partners Launch MD Start III Medtech Acceleration Fund at €48M

Sofinnova Partners, a leading European venture capital firm specialized in Life Sciences, announced the launch of MD Start III, which closed above its original target of €40 million.

May 21, 2019
·
3 min read
EXUMA Biotechnology’s Affiliate Shanghai PerHum Therapeutics Announces Preliminary Results of Two First-in-Human Solid Tumor CAR-T Products

Data Supports Continued Dose Escalation and Further Investigation in Metastatic Renal Cell Carcinoma (mRCC)

May 21, 2019
·
3 min read
Business

Comp Resource Group Receives 2019 Best of Delray Beach Award, Recognized for a 4th Straight Year

Comp Resource Group has been recognized and awarded the 2019 Best of Delray Beach Award as the top Recruiting Agency by the Delray Beach Awards Program.

May 21, 2019
·
1 min read
Drug Development

Nordic Nanovector: Archer-1 Phase 1b Betalutin®/Rituximab Combination Trial Advances to Next Cohort

Nordic Nanovector ASA announces that following a safety review of the first patients in the ongoing Archer-1 trial investigating Betalutin® in combination with rituximab in second-line follicular lymphoma, the Betalutin® dose has been escalated to 15 MBq/kg for the next cohort of patients.

May 21, 2019
·
4 min read
Biotech Bay

Cala Health Raises $50 Million Series C Funding

Investment will fund the commercial introduction of Cala Trio and expansion of the therapeutic platform

May 21, 2019
·
3 min read
Drug Development

First Sublingual Ketamine Drug for Treatment of Acute Pain to be Evaluated in End-of-Phase 2 Meeting with FDA

iX Biopharma Ltd announced that following the completion of its Phase 2 clinical study on Wafermine, a sublingual racemic ketamine wafer for the treatment of acute moderate to severe pain, the U.S. Food and Drug Administration has scheduled the End-of-Phase 2 meeting with the Company in the third quarter of 2019.

May 21, 2019
·
5 min read